Importation of FDA Approved Human Prescription Drugs, Including Biological Products, and Combination Products

Introduction

The United States Food and Drug Administration (FDA) regulates the importation of human prescription drugs, biological products, and combination products to ensure their safety, efficacy, and quality. The process of importing FDA-approved pharmaceutical products involves adherence to specific regulatory requirements and compliance with current good manufacturing practices (CGMP). This guide provides comprehensive information on the importation process for these products into the United States.

Regulatory Framework

The importation of FDA-approved human prescription drugs is governed by several key pieces of legislation including the Food, Drug, and Cosmetic Act (FD&C Act). The FDA implements and enforces these regulations through various Centers and Offices, with primary oversight provided by the Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and the Office of Regulatory Affairs (ORA).

Importers must comply with 21 CFR Part 1 regarding the registration of food, drug, device, and cosmetic establishments, among other relevant regulations. Under section 801(e) of the FD&C Act, drug imports are subject to specific requirements regarding their approval status and whether they were manufactured in accordance with FDA requirements.

Product Categories

Human Prescription Drugs

FDA-approved human prescription drugs include medications that require a prescription from a licensed healthcare provider for use. These drugs undergo rigorous review processes before receiving FDA approval. For importation purposes, these products must be listed in the FDA's Orange Book and have valid National Drug Codes (NDCs).

Biological Products

Biological products are distinct from conventional drugs and include a wide range of products such as vaccines, blood products, allergenic extracts, and therapeutic proteins. The Public Health Service Act (PHS Act) governs most biologics. Importers must pay close attention to specific requirements outlined in 21 CFR Part 600-680.

Combination Products

Combination products consist of two or more regulated components (drug, device, and/or biological product) combined to produce a single entity. These products present unique regulatory challenges as they may be subject to requirements from multiple FDA centers. The regulatory pathway for combination products depends on the primary mode of action of the combined product.

Importation Requirements

Product Approvals

Prior to importation, human prescription drugs must be approved under an FDA New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). Biological products require approval under a Biologics License Application (BLA). Combination products must have appropriate marketing authorization based on their classification. Products without proper approval may be subject to refusal of admission.

Registration Requirements

Both foreign manufacturers and initial U.S. importers must register their establishments with the FDA. The registration includes the submission of detailed information about the facility, contact individuals, and types of products manufactured or handled. This information must be updated annually or when changes occur.

Drug Listing Requirements

Importers must ensure that all commercial drug products are properly listed with the FDA. Drug listing requirements include submission of specific product information such as the proprietary name, established name, dosage form, route of administration, and labeler code. Accurate and up-to-date listings facilitate efficient processing at the border.

Documentation Submission

Importers are required to submit specific documentation for FDA review prior to or at the time of importation. These submissions include:

• Entry documentation filed through the Automated Commercial System (ACS)
• Product-specific information such as NDC codes and lot numbers
• Documentation of FDA approval status (NDA/ANDA/BLA numbers)
• Statements of compliance with current good manufacturing practices
• Certificates of analysis for each shipment
• Prior notices submitted through the FDA Prior Notice System Interface (PNSI)

Quality and Compliance Considerations

Imported FDA-approved drugs must meet the same rigorous quality standards as domestically produced pharmaceuticals. The FDA may conduct foreign inspections to verify compliance with cGMP requirements. Importers should establish robust quality management systems that include:

• Regular supplier audits and assessments
• Comprehensive testing of incoming materials and finished products
• Proper storage and transportation controls
• Effective product tracking and recall procedures
• Adverse event monitoring and reporting mechanisms

Temperature-sensitive products require special attention to cold chain management throughout the importation process. The FDA has issued guidance on temperature excursions that can affect product quality and stability.

Importation for Personal Use

While generally prohibited, the FDA may exercise enforcement discretion regarding the importation of small quantities of FDA-approved drugs for personal use under specific circumstances. This may apply to:

• Products not approved in the U.S. but approved in other countries
• Serious conditions for which effective treatment may not be available domestically
• Situations where there is no commercial promotion or distribution
• Quantities appropriate for personal use (typically 90-day supply or less)

Even in these cases, importers should be aware of risks related to product authenticity, proper storage conditions, and potential legal implications.

Recent Regulatory Updates

The regulatory landscape for pharmaceutical importation continues to evolve. Recent developments include:

• The implementation of the FDA Reauthorization Act of 2017 (FDARA) provisions that strengthen the agency's oversight of imported pharmaceuticals
• Enhanced requirements for imported drug security under the Drug Supply Chain Security Act (DSCSA)
• New guidance on voluntary nationwide remote regulatory assessments of foreign manufacturers
• Updated compliance policies related to importation of certain drugs under section 804 of the FD&C Act

Importers should regularly monitor FDA communications and guidance documents to stay informed of evolving requirements that may impact their operations.

Best Practices for Successful Importation

To facilitate successful importation of FDA-approved human prescription drugs, biological products, and combination products, companies should adopt the following practices:

1. Maintain current registrations and listings
2. Submit accurate and complete prior notices
3. Implement robust supply chain security measures
4. Conduct regular compliance self-assessments
5. Solicit expert regulatory guidance when necessary
6. Engage with FDA through appropriate channels when issues arise
7. Train relevant personnel on regulatory requirements
8. Develop and implement detailed standard operating procedures
9. Establish effective communication with foreign manufacturers
10. Maintain comprehensive records of all importation activities

Conclusion

The importation of FDA-approved human prescription drugs, biological products, and combination products requires careful attention to regulatory requirements and quality standards. By maintaining compliance with FDA regulations and implementing robust quality management systems, importers can help ensure the timely and efficient delivery of safe and effective pharmaceutical products to the U.S. market while supporting public health objectives.